Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Peptor
Rehovot, Israel
- Ownership
- Private
- Development stage
- Other
01
Overview
Peptor was an Israeli biopharmaceutical company focused on developing peptide-based therapeutics using its proprietary SCAPL technology. Its lead programs targeted autoimmune diseases such as diabetes and rheumatoid arthritis. The company’s most advanced assets were discontinued prior to its merger with DeveloGen in May 2004. No products reached commercialization.
- Therapeutic areas
- GastroenterologyCardiovascularImmunologyEndocrinology
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Partnerships
Aventis co-development partnership for a diabetes drug targeting latent autoimmune diabetes in adults and type I diabetes
Beyond the preview
Go deeper on Peptor.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptor.